Cannabis Man podcast highlights UC researcher

As more states legalize recreational and medical cannabis use, more research is needed into the effect of cannabis on its users.

LaTrice Montgomery, PhD, research associate professor in the Addiction Sciences Division of the Department of Psychiatry and Behavioral Neuroscience in the University of Cincinnati College of Medicine, is one of the nation's leading cannabis researchers and was recently featured on the Cannabis Man podcast.

In the podcast interview, Montgomery discussed a variety of topics, including the recent industry guideline that researchers should use 5 milligrams of THC as a standard unit for measuring and reporting purposes in clinical research. Montgomery said a lack of a clear standard has held the field of research back, but there are still issues to contend with since the way cannabis is ingested (smoking versus edibles, for example) can change how it affects a person.

"The variation in types of products makes it difficult when trying to see how intoxicated a person is or how it impacts you," Montgomery told the podcast. "It’s hard to study because people present with so many different types of products, how much they used, some people may use just a little bit, some people may use a lot."

Montgomery also spoke on how cannabis use disorder is defined, the issues that can come about from combining cannabis and tobacco use and about her ongoing Twitter-based intervention research for young adults.

Listen to the Cannabis Man podcast. (Podcast is also available on platforms including Spotify, Apple Podcasts and Pocket Casts.)

Read more about Montgomery's recent research.

Featured photo at top courtesy of Unsplash.

Related Stories

1

Trial results support weekly buprenorphine treatment of opioid use disorder during pregnancy

March 16, 2026

Supported by the National Institutes of Health (NIH), researchers led by the University of Cincinnati's John Winhusen published clinical trial results in JAMA Internal Medicine that found administering weekly injectable extended-release buprenorphine for treatment of opioid use disorder during pregnancy led to higher rates of abstinence from illicit opioids than buprenorphine given daily under the tongue, one of the standard methods of treatment.